MedTrace Logo

Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease

NCT00675090 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2017-07-07

No results posted yet for this study

Summary

This is a safety and tolerability study to investigate the effect of GSK239512 on mild to moderate Alzheimers disease patients. The dose of GSK239512 will be titrated to reach the most well tolerated dose in the patients.

Conditions

Interventions

DRUG

GSK239512

GSK239512 oral tablets once a day

DRUG

Placebo

Placebo tablets to match once a day

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-21
Primary Completion
2009-06-16
Completion
2009-06-16

Countries

  • Australia
  • Czechia
  • South Korea
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00675090 on ClinicalTrials.gov